Cover Image
市場調查報告書

抗生素市場規模與預測:各類藥物(頭孢菌素,青黴素,氟喹諾酮類,大環內酯類,碳青黴烯類,氨基糖苷類,磺胺類藥物),各作用機制,及市場區隔預測

Antibiotics Market Analysis By Drug Class (Cephalosporins, Penicillins, Fluoroquinolones, Macrolides, Carbapenems, Aminoglycosides, Sulfonamides), By Mechanism Of Action, And Segment Forecasts To 2024

出版商 Grand View Research, Inc. 商品編碼 398842
出版日期 內容資訊 英文 119 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
抗生素市場規模與預測:各類藥物(頭孢菌素,青黴素,氟喹諾酮類,大環內酯類,碳青黴烯類,氨基糖苷類,磺胺類藥物),各作用機制,及市場區隔預測 Antibiotics Market Analysis By Drug Class (Cephalosporins, Penicillins, Fluoroquinolones, Macrolides, Carbapenems, Aminoglycosides, Sulfonamides), By Mechanism Of Action, And Segment Forecasts To 2024
出版日期: 2016年10月06日 內容資訊: 英文 119 Pages
簡介

本報告提供抗生素市場相關調查,市場趨勢與各類藥物,設備,各作用機制,及各地區預測,競爭趨勢,及加入此市場的主要企業簡介等彙整資料。

第1章 調查方法與範圍

第2章 摘要整理

第3章 市場摘要

第4章 市場變數,趨勢,範圍

  • 市場區隔和範圍
  • 促進要素分析
  • 阻礙要素分析
  • 滲透率與成長預測製圖
  • SWOT分析
    • 政治
    • 經濟
    • 技術性

第5章 市場類別1:各類藥物預測與趨勢分析

  • 各類藥物趨勢分析與市場佔有率
  • 各類藥物市場規模,預測,及趨勢分析
    • 頭孢菌素
    • 青黴素
    • 氟喹諾酮類
    • 大環內酯類
    • 碳青黴烯類
    • 氨基糖苷類
    • 磺胺類藥物
    • 其他

第6章 市場類別2:各作用機制預測與趨勢分析

  • 各作用機制趨勢分析與市場佔有率
  • 各作用機制市場規模,預測,及趨勢分析
    • 細胞牆合成抑制劑
    • 蛋白質合成抑制劑
    • DNA合成抑制劑
    • RNA合成抑制劑
    • 未膽酸合成抑制劑
    • 葉酸合成抑制劑

第7章 市場類別3:各地區預測與趨勢分析

  • 各地區市場分析與市場佔有率
    • 北美
    • 歐洲
    • 亞太地區
    • 南美
    • 中東·非洲

第8章 競爭環境

  • 策略性架構
  • 企業簡介
    • Getinge Group
    • Hill-Rom
    • Invacare Corporation
    • Joerns Healthcare, LLC
    • Argo Medical, Inc.
    • Prism Medical
    • DJO Global
    • V.Guldmann A/S
    • Spectra Care Group
    • Drive Medical

圖表

目錄
Product Code: GVR-1-68038-149-8

The antibiotics market is expected to reach USD 57.0 billion by 2024, according to the new report by Grand View Research, Inc. Rising prevalence of infectious diseases especially in developing regions such as Asia Pacific and MEA is anticipated to contribute towards market growth.

More than 15.0% of the deaths, in children below the age of five, are estimated to be due to pneumonia and according to the statistics provided by the WHO about 9.2 million deaths were recorded in 2015. Similar to tuberculosis, the highest prevalence of the disease is identified to be in the South Asian and Sub-Saharan regions. Currently, the required antibiotic treatment is available only to one third of the infected population, thereby increasing the disease burden.

Government reforms specific to antibiotics such as the Generating Antibiotics Incentives Now (GAIN) Act in the U.S. are projected to help market growth over the forecast period. This further expected facilitate development of advanced drugs.

On the contrary, uncertain regulatory policies are likely to hinder the growth of this vertical impacting market growth significantly. In 2013, the U.S. FDA revised the guidance for registration trials for drugs used in the treatment of acute bacterial skin and skin structure infections. The guidance states the use of short term measures of anti-infective efficacy (percent reduction in lesion size at 48 to 72 hours) as opposed to long term measures such as resolution of infection at 10-14 days, which is termed as Test to Cure or TOC.

Further Key Findings From the Study Suggest:

  • Antibiotic segment including tetracyclines, imidazoles, lincosamides and monoclonal antibodies held commanding share in 2015 and are also anticipated to grow at a lucrative growth rate over the forecast period
  • Development of monoclonal antibodies for antibiotic resistant microorganism is key highlight of this segment. Increasing incidences of pneumonia, blood stream infections, and urinary tract infections (UTI) are anticipated to foster the usage of carbapenems class of antibiotics.
  • Cell wall synthesis inhibitors dominated the mechanism outlook in 2015. Majority of the antibiotics such as penicillins, cephalosporins and carbapenems forms the cell wall synthesis inhibitor class.
  • RNA synthesis inhibitors as well as folic acid synthesis inhibitors are anticipated to witness healthy growth over the forecast period. Development of several antiviral drugs which inhibit transcription and reverse transcription process are anticipated to support the growth. Folic acid inhibitor sulfa drugs are anticipated to grow as they have wide application scope.
  • Asia Pacific on account of huge population base, high prevalence of infectious diseases, regulation reforms and greater usage of generic medicine held commanding share in 2015.
  • Latin America, especially Brazil with strong growth in pharmaceutical sector is also projected to exhibit remunerative growth. Outbreak of certain viruses such as Ebola in African region also contributed towards the significant growth of MEA region.
  • Some of the key players in this vertical are Pfizer, Inc., Janssen Pharmaceuticals, Abbott, GlaxoSmithKline plc, Sanofi, Novartis AG, Bayer AG, Bristol Myers Squibb Company, Eli Lilly and Company and Astellas Pharma, Inc.

Table of Content

Chapter 1. Research Methodology

  • 1.1. Research Methodology
  • 1.2. Research Scope & Assumptions
  • 1.3. List of Data Sources

Chapter 2. Executive Summary

Chapter 3. Market Summary

Chapter 4. Market Variables, Trends & Scope

  • 4.1. Market Segmentation & Scope
  • 4.2. Market Driver Analysis
  • 4.3. Market Restraint Analysis
  • 4.4. Penetration & Growth Prospect Mapping
  • 4.5. SWOT Analysis, By Factor
    • 4.5.1. Political
    • 4.5.2. Economic
    • 4.5.3. Technology

Chapter 5. Market Categorization 1: Drug Class Estimates & Trend Analysis

  • 5.1. Drug Class Movement Analysis & Market Share, 2015 & 2024
  • 5.2. Market Size & Forecasts and Trend Analyses, 2013 to 2024 For the Following Drug Class:
    • 5.2.1. Cephalosporins
    • 5.2.2. Penicillins
    • 5.2.3. Fluoroquinolones
    • 5.2.4. Macrolides
    • 5.2.5. Carbapenems
    • 5.2.6. Aminoglycosides
    • 5.2.7. Sulfonamides
    • 5.2.8. Other

Chapter 6. Market Categorization 2: Mechanism Estimates & Trend Analysis

  • 6.1. Mechanism Movement Analysis & Market Share, 2015 & 2024
  • 6.2. Market Size & Forecasts and Trend Analyses, 2013 to 2024 For the Following Mechanim:
    • 6.2.1. Cell Wall Synthesis Inhibitors
    • 6.2.2. Protein Synthesis Inhibitors
    • 6.2.3. DNA Synthesis Inhibitors
    • 6.2.4. RNA Synthesis Inhibitors
    • 6.2.5. Mycolic Acid Inhibitors
    • 6.2.6. Folic Acid Synthesis Inhibitors

Chapter 7. Market Categorization 2: Regional Estimates & Trend Analysis

  • 7.1. Regional Movement Analysis & Market Share, 2015 & 2024
  • 7.2. Market Size & Forecasts and Trend Analyses, 2013 to 2024 for the following regions:
    • 7.2.1. North America
      • 7.2.1.1. U.S.
      • 7.2.1.2. Canada
    • 7.2.2. Europe
      • 7.2.2.1. UK
      • 7.2.2.2. Germany
    • 7.2.3. Asia Pacific
      • 7.2.3.1. Japan
      • 7.2.3.2. China
    • 7.2.4. Latin America
      • 7.2.4.1. Brazil
      • 7.2.4.2. Mexico
    • 7.2.5. MEA
      • 7.2.5.1. South Africa

Chapter 8. Competitive Landscape

  • 8.1. Strategy Framework
  • 8.2. Company Profiles
    • 8.2.1. Getinge Group (ArjoHuntleigh)
      • 8.2.1.1. Company overview
      • 8.2.1.2. Financial performance
      • 8.2.1.3. Product benchmarking
      • 8.2.1.4. Strategic initiatives
    • 8.2.2. Hill-Rom
      • 8.2.2.1. Company overview
      • 8.2.2.2. Financial performance
      • 8.2.2.3. Product benchmarking
      • 8.2.2.4. Strategic initiatives
    • 8.2.3. Invacare Corporation
      • 8.2.3.1. Company overview
      • 8.2.3.2. Financial performance
      • 8.2.3.3. Product benchmarking
      • 8.2.3.4. Strategic initiatives
    • 8.2.4. Joerns Healthcare, LLC
      • 8.2.4.1. Company overview
      • 8.2.4.2. Financial performance
      • 8.2.4.3. Product benchmarking
      • 8.2.4.4. Strategic initiatives
    • 8.2.5. Argo Medical, Inc.
      • 8.2.5.1. Company overview
      • 8.2.5.2. Financial performance
      • 8.2.5.3. Product benchmarking
      • 8.2.5.4. Strategic initiatives
    • 8.2.6. Prism Medical
      • 8.2.6.1. Company overview
      • 8.2.6.2. Financial performance
      • 8.2.6.3. Product benchmarking
      • 8.2.6.4. Strategic initiatives
    • 8.2.7. DJO Global
      • 8.2.7.1. Company overview
      • 8.2.7.2. Financial performance
      • 8.2.7.3. Product benchmarking
      • 8.2.7.4. Strategic initiatives
    • 8.2.8. V.Guldmann A/S
      • 8.2.8.1. Company overview
      • 8.2.8.2. Financial performance
      • 8.2.8.3. Product benchmarking
      • 8.2.8.4. Strategic initiatives
    • 8.2.9. Spectra Care Group
      • 8.2.9.1. Company overview
      • 8.2.9.2. Financial performance
      • 8.2.9.3. Product benchmarking
      • 8.2.9.4. Strategic initiatives
    • 8.2.10. Drive Medical
      • 8.2.10.1. Company overview
      • 8.2.10.2. Financial performance
      • 8.2.10.3. Product benchmarking
      • 8.2.10.4. Strategic initiatives

List of Tables

  • TABLE 1: Antibiotic drugs under Phase III clinical trial, 2015
  • TABLE 2: Public-private and Private-private agreements:
  • TABLE 3: North America antibiotics market estimates, by mechanism, 2013 - 2015 (USD Million)
  • TABLE 4: North America antibiotics market forecasts, by mechanism, 2016 - 2024 (USD Million)
  • TABLE 5: North America antibiotics market estimates, by drug class, 2013 - 2015 (USD Million)
  • TABLE 6: North America antibiotics market estimates, by drug class, 2013 - 2015 (USD Million)
  • TABLE 7: U.S. antibiotics market estimates, by mechanism, 2013 - 2015 (USD Million)
  • TABLE 8: U.S. antibiotics market forecasts, by mechanism, 2016 - 2024 (USD Million)
  • TABLE 9: U.S. antibiotics market estimates, by drug class, 2013 - 2015 (USD Million)
  • TABLE 10: U.S. antibiotics market estimates, by drug class, 2013 - 2015 (USD Million)
  • TABLE 11: Canada antibiotics market estimates, by mechanism, 2013 - 2015 (USD Million)
  • TABLE 12: Canada antibiotics market forecasts, by mechanism, 2016 - 2024 (USD Million)
  • TABLE 13: Canada antibiotics market estimates, by drug class, 2013 - 2015 (USD Million)
  • TABLE 14: Canada antibiotics market estimates, by drug class, 2013 - 2015 (USD Million)
  • TABLE 15: Europe antibiotics market estimates, by mechanism, 2013 - 2015 (USD Million)
  • TABLE 16: Europe antibiotics market forecasts, by mechanism, 2016 - 2024 (USD Million)
  • TABLE 17: Europe antibiotics market estimates, by drug class, 2013 - 2015 (USD Million)
  • TABLE 18: Europe antibiotics market estimates, by drug class, 2013 - 2015 (USD Million)
  • TABLE 19: UK antibiotics market estimates, by mechanism, 2013 - 2015 (USD Million)
  • TABLE 20: UK antibiotics market forecasts, by mechanism, 2016 - 2024 (USD Million)
  • TABLE 21: UK antibiotics market estimates, by drug class, 2013 - 2015 (USD Million)
  • TABLE 22: UK antibiotics market estimates, by drug class, 2013 - 2015 (USD Million)
  • TABLE 23: Germany antibiotics market estimates, by mechanism, 2013 - 2015 (USD Million)
  • TABLE 24: Germany antibiotics market forecasts, by mechanism, 2016 - 2024 (USD Million)
  • TABLE 25: Germany antibiotics market estimates, by drug class, 2013 - 2015 (USD Million)
  • TABLE 26: Germany antibiotics market estimates, by drug class, 2013 - 2015 (USD Million)
  • TABLE 27: Asia Pacific antibiotics market estimates, by mechanism, 2013 - 2015 (USD Million)
  • TABLE 28: Asia Pacific antibiotics market forecasts, by mechanism, 2016 - 2024 (USD Million)
  • TABLE 29: Asia Pacific antibiotics market estimates, by drug class, 2013 - 2015 (USD Million)
  • TABLE 30: Asia Pacific antibiotics market estimates, by drug class, 2013 - 2015 (USD Million)
  • TABLE 31: Japan antibiotics market estimates, by mechanism, 2013 - 2015 (USD Million)
  • TABLE 32: Japan antibiotics market forecasts, by mechanism, 2016 - 2024 (USD Million)
  • TABLE 33: Japan antibiotics market estimates, by drug class, 2013 - 2015 (USD Million)
  • TABLE 34: Japan antibiotics market estimates, by drug class, 2013 - 2015 (USD Million)
  • TABLE 35: China antibiotics market estimates, by mechanism, 2013 - 2015 (USD Million)
  • TABLE 36: China antibiotics market forecasts, by mechanism, 2016 - 2024 (USD Million)
  • TABLE 37: China antibiotics market estimates, by drug class, 2013 - 2015 (USD Million)
  • TABLE 38: China antibiotics market estimates, by drug class, 2013 - 2015 (USD Million)
  • TABLE 39: India antibiotics market estimates, by mechanism, 2013 - 2015 (USD Million)
  • TABLE 40: India antibiotics market forecasts, by mechanism, 2016 - 2024 (USD Million)
  • TABLE 41: India antibiotics market estimates, by drug class, 2013 - 2015 (USD Million)
  • TABLE 42: India antibiotics market estimates, by drug class, 2013 - 2015 (USD Million)
  • TABLE 43: Latin America antibiotics market estimates, by mechanism, 2013 - 2015 (USD Million)
  • TABLE 44: Latin America antibiotics market forecasts, by mechanism, 2016 - 2024 (USD Million)
  • TABLE 45: Latin America antibiotics market estimates, by drug class, 2013 - 2015 (USD Million)
  • TABLE 46: Latin America antibiotics market estimates, by drug class, 2013 - 2015 (USD Million)
  • TABLE 47: Brazil antibiotics market estimates, by mechanism, 2013 - 2015 (USD Million)
  • TABLE 48: Brazil antibiotics market forecasts, by mechanism, 2016 - 2024 (USD Million)
  • TABLE 49: Brazil antibiotics market estimates, by drug class, 2013 - 2015 (USD Million)
  • TABLE 50: Brazil antibiotics market estimates, by drug class, 2013 - 2015 (USD Million)
  • TABLE 51: Mexico antibiotics market estimates, by mechanism, 2013 - 2015 (USD Million)
  • TABLE 52: Mexico antibiotics market forecasts, by mechanism, 2016 - 2024 (USD Million)
  • TABLE 53: Mexico antibiotics market estimates, by drug class, 2013 - 2015 (USD Million)
  • TABLE 54: Mexico antibiotics market estimates, by drug class, 2013 - 2015 (USD Million)
  • TABLE 55: MEA antibiotics market estimates, by mechanism, 2013 - 2015 (USD Million)
  • TABLE 56: MEA antibiotics market forecasts, by mechanism, 2016 - 2024 (USD Million)
  • TABLE 57: MEA antibiotics market estimates, by drug class, 2013 - 2015 (USD Million)
  • TABLE 58: MEA antibiotics market estimates, by drug class, 2013 - 2015 (USD Million)
  • TABLE 59: South Africa antibiotics market estimates, by mechanism, 2013 - 2015 (USD Million)
  • TABLE 60: South Africa antibiotics market forecasts, by mechanism, 2016 - 2024 (USD Million)
  • TABLE 61: South Africa antibiotics market estimates, by drug class, 2013 - 2015 (USD Million)
  • TABLE 62: South Africa antibiotics market estimates, by drug class, 2013 - 2015 (USD Million)

List of Figures

  • FIG. 1: Market research process
  • FIG. 2: Information procurement
  • FIG. 3: Primary research pattern
  • FIG. 4: Market research approaches
  • FIG. 5: Value chain based sizing & forecasting
  • FIG. 6: QFD modelling for market share assessment
  • FIG. 7: Market summary, USD Million
  • FIG. 8: Market trends & outlook
  • FIG. 9: Market segmentation & scope
  • FIG. 10: Market driver relevance analysis (Current & future impact)
  • FIG. 11: Market restraint relevance analysis (Current & future impact)
  • FIG. 12: Penetration & growth prospect mapping
  • FIG. 13: SWOT Analysis, By Factor (political & legal, economic and technological)
  • FIG. 14: Porter's Five Forces Analysis
  • FIG. 15: Antibiotics market mechanism outlook key takeaways
  • FIG. 16: Antibiotics market: Mechanism movement analysis
  • FIG. 17: Cell wall synthesis inhibitors market, 2013 - 2024 (USD Million)
  • FIG. 18: Protein synthesis inhibitors market, 2013 - 2024 (USD Million)
  • FIG. 19: DNA synthesis inhibitors market, 2013 - 2024 (USD Million)
  • FIG. 20: RNA synthesis inhibitors market, 2013 - 2024 (USD Million)
  • FIG. 21: Mycolic acid inhibitors market, 2013 - 2024 (USD Million)
  • FIG. 22: Folic acid synthesis inhibitors market, 2013 - 2024 (USD Million)
  • FIG. 23: Antibiotics market drug class outlook key takeaways
  • FIG. 24: Antibiotics market: Drug class movement analysis
  • FIG. 25: Cephalosporins market, 2013 - 2024 (USD Million)
  • FIG. 26: Penicillin market, 2013 - 2024 (USD Million)
  • FIG. 27: Fluoroquinolones market, 2013 - 2024 (USD Million)
  • FIG. 28: Macrolides market, 2013 - 2024 (USD Million)
  • FIG. 29: Carbapenems market, 2013 - 2024 (USD Million)
  • FIG. 30: Aminoglycosides market, 2013 - 2024 (USD Million)
  • FIG. 31: Sulfonamides market, 2013 - 2024 (USD Million)
  • FIG. 32: Other antibiotics market, 2013 - 2024 (USD Million)
  • FIG. 33: Regional market place: Key takeaways
  • FIG. 34: Regional outlook, 2015 & 2024
  • FIG. 35: North America antibiotics market, 2013 - 2024 (USD Million)
  • FIG. 36: U.S. antibiotics market, 2013 - 2024 (USD Million)
  • FIG. 37: Canada antibiotics market, 2013 - 2024 (USD Million)
  • FIG. 38: Europe antibiotics market, 2013 - 2024 (USD Million)
  • FIG. 39: UK antibiotics market, 2013 - 2024 (USD Million)
  • FIG. 40: Germany antibiotics market, 2013 - 2024 (USD Million)
  • FIG. 41: Asia Pacific antibiotics market, 2013 - 2024 (USD Million)
  • FIG. 42: Japan antibiotics market, 2013 - 2024 (USD Million)
  • FIG. 43: China antibiotics market, 2013 - 2024 (USD Million)
  • FIG. 44: India antibiotics market, 2013 - 2024 (USD Million)
  • FIG. 45: Latin America antibiotics market, 2013 - 2024 (USD Million)
  • FIG. 46: Brazil antibiotics market, 2013 - 2024 (USD Million)
  • FIG. 47: Mexico antibiotics market, 2013 - 2024 (USD Million)
  • FIG. 48: MEA antibiotics market, 2013 - 2024 (USD Million)
  • FIG. 49: South Africa antibiotics market, 2013 - 2024 (USD Million)
Back to Top